title: Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-alpha have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects?
authors.forename: Franco
authors.initials: F
authors.lastname: de' Clari
authors.forename: I
authors.initials: I
authors.lastname: Salani
authors.forename: E
authors.initials: E
authors.lastname: Safwan
authors.forename: A
authors.initials: A
authors.lastname: Giannacco
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D000075202:Contraindications; D003645:Death, Sudden / Q000209:etiology*; D004562:Electrocardiography; D006321:Heart / Q000187:drug effects*; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab